
New findings on spinal muscular atrophy
Researchers investigate the impact on the immune system.

TWINCORE was founded in 2008 by the Helmholtz Centre for Infection Research and the Hannover Medical School. We combine the expertise of medical professionals and scientists from a wide range of disciplines to find answers to the pressing questions in infection research. Our focus: translational research – the bridge between basic science and clinical application.

Researchers investigate the impact on the immune system.

How bacteria develop resistance to antisense antibiotics - and how future therapies can be designed to reduce the risk of resistance

A team of researchers from Hamburg, Berlin, Göttingen and Hannover has provided evidence of possible cross-protection offered by an already authorised Zaire Ebola virus vaccine.
We conduct translational infection research to improve the prevention, diagnosis and treatment of infectious diseases in humans. We focus on three areas that characterize our research work. Find out here how we proceed and what results we achieve.
Under the leadership of our best scientists, various labs are working on different projects within our research topics.
Grondman I, Koeken V, Couwenbergh T, Karageorgos A, Li W, Antonakos N, Zhang B, Damoraki G, van der Heijden W, Xu C, Giamarellos-Bourboulis E, Li Y, Netea M
Krooss S, Yang T, Yuan Q, Drick N, Sgodda M, Held J, Behrendt P, Hartleben B, Koczulla R, Ma X, Liu Y, Wedemeyer H, Janciauskiene S, Di Donato N, Cantz T, Wang Z, Wu Y, Hoeper M, Xia Q, Ott M
Biesel A, Shandheep A, Pavlou A, Busker L, Koch M, Kopliku V, Maisel K, Boese A, Skerra J, Schröder L, Neubert L, Schneider-Daum N, Loretz B, Kalinke U, Lehr C
We are investigating how the association of HCV with lipoproteins contributes to the persistence of the virus by influencing entry into liver cells and protecting against antibodies. The aim is to gain new insights for the development of an HCV vaccine.
We are investigating why HCV infections sometimes heal spontaneously, but often become chronic, and why RSV infections are severe in some children. We use modern sequencing technologies to analyze the genetic characteristics of hosts and pathogens in order to understand susceptibility.
Together with the Department of Structural Biology at the University of Lübeck, human, strongly neutralizing antibodies against HEV were identified and characterized for the first time. These showed a protective effect in the mouse model and are currently being further developed for clinical application, including mRNA-based application methods.
By applying statistical genetics methods to pathogen genome sequences, we aim to identify and validate genetic determinants of phenotypes such as pathogenicity, virulence and antibiotic resistance, e.g. in E. coli and P. aeruginosa.
There are currently no events.

